Medulloblastoma is the most frequent malignant brain tumor in children. Four medulloblastoma molecular subgroups, MB SHH , MB WNT , MB GRP3 and MB GRP4 , have been identified by integrated high-throughput platforms. Recently, a 22-gene panel NanoString-based assay was developed for medulloblastoma molecular subgrouping, but the robustness of this assay has not been widely evaluated. Mutations in the gene for human telomerase reverse transcriptase (hTERT) have been found in medulloblastomas and are associated with distinct molecular subtypes. This study aimed to implement the 22-gene panel in a Brazilian context, and to associate the molecular profile with patients' clinical-pathological features. Formalin-fixed, paraffin-embedded (FFPE) medulloblastoma samples (n = 104) from three Brazilian centers were evaluated. Expression profiling of the 22-gene panel was performed by NanoString and a Canadian series (n = 240) was applied for training phase. hTERT mutations were analyzed by PCR followed by direct Sanger sequencing and the molecular profile was associated with patients' clinicopathological features. Overall, 65% of the patients were male, average age at diagnosis was 18 years and 7% of the patients presented metastasis at diagnosis. The molecular classification was attained in 100% of the cases, with the following frequencies: MB SHH (n = 51), MB WNT (n = 19), MB GRP4 (n = 19) and MB GRP3 (n = 15). The MB SHH and MB GRP3 subgroups were associated with older and younger patients, respectively. The MB GRP4 subgroup exhibited the lowest 5-year cancer-specific overall survival (OS), yet in the multivariate analysis, only metastasis at diagnosis and surgical resection were associated with OS. hTERT mutations were detected in 29% of the cases and were associated with older patients, increased hTERT expression and MB SHH subgroup. The 22-gene panel provides a reproducible assay for molecular subgrouping of medulloblastoma FFPE samples in a routine setting and is well-suited for future clinical trials.
INTRODUCTION
Medulloblastoma is the most frequent malignant brain tumor in children, accounting for approximately 20% of all pediatric intracranial tumors. 1, 2 Recent estimates of the occurrence of central nervous system tumors, such as medulloblastoma, suggest they represent about 2.5% of the newly diagnosed cases of pediatric neoplasms in Brazil. 3 In adults, medulloblastomas are less common, with a peak of incidence between 20 and 35 years old. 4 Advances in the treatment of medulloblastoma have improved survival rates over the last few decades. However, the disease outcome remains very poor, with both 5-year overall and event-free survivals for high-risk patients being about 25-44%. [5] [6] [7] Histologically, medulloblastomas can be classified as classic, the most common subtype (70%), followed by the desmoplastic (10-20%), anaplastic/large-cell subtype (5-10%) and extensive nodularity subtype (5-10%). 5, 8 The major prognostic factors are histology, age at diagnosis, presence of metastatic disease, and the extent of tumor volume at resection. 9, 10 Younger medulloblastoma patients, who have evidence of metastasis at diagnosis, residual disease after surgery or large cells/anaplastic histology, are associated with an unfavorable prognosis. 9, 11, 12 Until recently, these clinical and pathological prognostic factors were used for defining overall disease risk, but newer combinations of clinical, pathological and molecular prognostic markers are providing a more accurate disease risk stratification. 13 Medulloblastomas can be molecularly classified based on specific genomic and genetic features. [14] [15] [16] Gene expression analysis using large cohorts of medulloblastomas has identified four molecular subgroups of medulloblastoma, namely WNT (MB WNT ), SHH (MB SHH ), group 3 (MB GRP3 ) and group 4 (MB GRP4 ). 14, 16, 17 Moreover, this molecular classification correlates with several clinicalpathological features, such as patient prognosis, histology and age at diagnosis. 10, 17 The MB WNT subgroup has a better prognosis, whereas MB GRP3 patients present with a poor prognosis. 18 MB WNT medulloblastomas can occur at all ages, but are infrequently seen in infants and are more common in children. The MB GRP4 subgroup is also more frequent in children, but it can also be seen in both infant and adult medulloblastoma. MB GRP3 tumors are frequent in infants and children, but are rare in adults, whereas MB SHH subgroups are very frequent in both infants and adults. 10, 17, 19 Thus, subgroup analysis using gene expression signatures is providing clinicians with a new tool for improved management of medulloblastoma patients. In addition to molecular signatures, gene alterations such as mutations in the promotor region of the gene for human telomerase reverse transcriptase (hTERT) have been described in about 20% of medulloblastomas, and they correlate with a worse prognosis. 20 Furthermore, the presence of hTERT promoter mutations is associated with a higher expression of hTERT gene in medulloblastomas, especially in non-infant MB SHH.
20-22
The nCounter ® system (NanoString Technologies, Seattle, WA, USA) is an automated high-throughput platform designed to evaluate mRNA expression. The mRNA expression levels are directly measured with a high sensitivity in a single multiplexed hybridization reaction. 23 The nCounter ® platform is particularly well-suited for expression analysis of formalin-fixed, paraffin-embedded (FFPE) samples, as the quality of these samples may be highly variable, producing low yields of highly degraded mRNA. 24 Furthermore, the nCounter ® technology does not require further validation, since it does not require enzymatic reactions, it generates reproducible results. 23 Northcott and colleagues constructed a 22-gene panel that could accurately distinguish medulloblastoma molecular subgroups using the nCounter ® platform. The 22 genes they selected have differential expressions associated with each molecular subgroup. 25 The aim of the present study was to implement the 22-gene panel for molecular classification of medulloblastomas from FFPE blocks using the nCounter ® technology in a Brazilian population, and to associate the molecular subgroups with the hTERT mutational status and clinicalpathological features of our cohort.
MATERIAL AND METHODS

Patients
Brazilian cases Table S1 ), we assessed both primary and metastatic tissues. The histologic diagnoses of all cases were reviewed by two expert neuropathologists in accordance with revised 2016 WHO classification, which has histologically defined medulloblastomas as classic, desmoplastic/nodular, extensive nodularity or large cell/anaplastic. 26 The summary of clinical-pathological and molecular features is presented in the Table S1 . This study was approved by the local ethics committee (#478/2011).
Canadian series
The molecular data of a series comprising 240 medulloblastomas from the Hospital for Sick Children, University of Toronto, Canada, was kindly provided by Dr. Michael Taylor, and were employed for class prediction. 25 
RNA isolation
RNA was isolated from three to five 10-μm-thick sections using RNeasy Mini kit (Qiagen, Venlo, Netherlands) following the manufacturer's instructions. Briefly, following deparaffinization steps, unstained slides were scraped upon a tumor area demarcated on a HE slide. All specimens were submitted to protease digestion followed by nucleic acid isolation followed by DNAse digestion and sample elution. RNA concentrations were assessed by spectrophotometry (NanoDrop; Thermo Fisher Scientific, Waltham, MA, USA) and a subset of samples were also evaluated by BioAnalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA).
The nCounter ® system (NanoString)
The medulloblastoma panel was carried out using the NanoString nCounter Elements™. The custom CodeSet was designed using characteristic genes for each medulloblastoma subgroup as previously employed: MB SHH -PDLIM3, EYA1, HHIP, ATOH1, SFRP1; MB WNT -WIF1, TNC, GAD1, DKK2, EMX2; MB GRP3 -IMPG2, GABRA5, EGFL11, NRL, MAB21L2, NPR3; MB GRP4 -KCNA1, EOMES, KHDRBS2, RBM24, UNC5D, OAS1 and three housekeeping genes (ACTB, GAPDH and LDHA). 25 In addition, 11 other cancer genes including hTERT gene were added to the gene panel CodeSet used in this study. The expression analysis of the hTERT gene was performed for the present study and the analyses of the other 10 genes will be further reported (manuscript in preparation). All procedures regarding sample preparation, hybridization, detection and scanning were performed according to the manufacturer's instructions (NanoString Technologies, Seattle, WA, USA). The custom probes (A and B) were designed by IDT (IDT Technologies), containing 35-50 base pairs each and probes were diluted to a final concentration of 0.6 nmol/L (probe A) and 3.0 nmol/L (probe B) to create the working probe pools. A total amount of 100-300 ng RNA was hybridized with probe pools, hybridization buffer and TagSet reagents and incubated at 67 C for 21 h. Then, samples were loaded to the nCounter ® PrepStation (NanoString), which automatically performs purification steps and cartridge preparation. Finally, the cartridges containing immobilized reporter complexes were transferred to nCounter ® Digital Analyzer (NanoString), a high-resolution setting, which captures up to 280 fields of view (FOVs) per sample providing all gene counts.
DNA isolation and hTERT mutational analysis
DNA was isolated from three to five sections each 10 μm thick using QIAmp DNA Mini kit (QIAgen) as previously reported. 20 DNA concentrations were assessed by spectrophotometry (NanoDrop). hTERT promoter hotspot mutations (−124 bp G > A and -146 bp G > A) were screened by PCR followed by Sanger sequencing as previously described. 20, 27 All samples with mutations were confirmed at least twice.
Data analysis
Reporter probe counts were captured by nCounter ® Digital
Analyzer and raw data was collected and pre-processed by nSolver™ Analysis Software v3.0 (NanoString). For data normalization, NanoStringNorm package was employed (version 18 November, 2015; http://cran.r-project.org/web/ packages/NanoStringNorm). 28 The normalization method basically consists of four major corrections, which are probelevel background correction, code-count normalization, background correction and sample content normalization by housekeeping genes. The NanoStringNorm package uncovers potential batch-effects, identifies background artifacts and assesses negative/positive controls. Each parameter for all normalizations is associated with plots and all results, diagnostics and expression values were outputted for statistical analyses, heatmaps design and use in class prediction methodologies.
For class prediction analysis of the Brazilian series (n = 104), the Canadian series (n = 240) was employed to establish a prediction dataset, since all samples had been previously classified for medulloblastoma molecular subgroups. 25 Raw data from all samples (Brazilian and Canadian series) were normalized and the gene expression values were defined. Normalized data were input for class prediction analysis using the Prediction Analysis for Microarrays (PAM) algorithm. 29 PAM is a statistical technique for class prediction from gene expression data using nearest shrunken centroids. Class prediction was performed using a machine learning method following these analytical phases: (i) training phase: data from Canadian series were considered for input by pairing with the expected output to train our model employing the PAM algorithm; (ii) validation phase: data from the Brazilian series employing the heatmap clustering as gold-standard were used for initial classification of medulloblastoma molecular subgroups applying the PAM method; (iii) test phase: application of our model to the Brazilian series for class prediction and probability results. For analysis of hTERT mRNA expression, MannWhitney test was applied for comparing wild-type and hTERT mutated cases. Survival analysis was carried out by Kaplan-Meier curves, which were compared by the log-rank test. For disease-specific overall survival (OS), patients who were lost to follow-up were censored considering their last follow-up visit, and patients who died due to external causes or surgical complications were censored considering death date as the last data entry. For all analyses, cancer-specific death was considered as the unfavorable event.
For pre-processing and normalization, statistical analyses, graph constructions, heatmap designs and class prediction, the KNIME v.3.2.0 software (KNIME GmbH, Konstanz, Germany) was employed in the R environment (R Foundation, Vienna, Austria). For survival analysis, the IBM SPSS Statistics for Windows version 21.0 (IBM, Armonk, NY, USA) and GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA) were employed. A Cox multivariate analysis considering age and gender as confounders was performed for disease-specific OS analysis. The level of significance for all analyses was 5%.
RESULTS
Clinicopathological features of Brazilian patients
We evaluated 104 tumors from patients diagnosed with medulloblastoma (Table 1; Table S1 ). Thirty-six (35%) patients were female and 67 (65%) were male (data were unavailable from one patient). The average age at diagnosis was 18 years old (range, 2-56 years), with 11 patients ≤ 4 years old, 55 cases between 5 and 19 years old, and 37 more than 20 years old (no available information for one patient). Clinical findings showed that 93% of the patients (92/99) did not have metastasis at diagnosis, whereas 7% (7/99) of the patients presented metastasis at diagnosis (data were not available for five cases). Additionally, 63% of the patients (59/94) underwent total surgical resection and 37% (35/94) partial surgical resection. For two patients, surgery was not performed and they were subjected to biopsy only (data were not available for eight cases). Histologic classification showed that 57% (59/104) had classic histology, 24% (25/104) desmoplastic/nodular histologic features, 4% (4/104) anaplastic/large cells, and 12% (13/104) extensive nodularity, and 1% (1/104) mixed histology. One case was not clearly defined and one case presented inconclusive histological features (Table 1;  Table S1 ).
Overall survival was associated with metastasis at diagnosis (P = 0.04) and surgical resection (P = 0.001; Table S2 ).
Classification of medulloblastoma molecular subgroups
We obtained conclusive results from all 106 FFPE samples that comprised 104 primary samples and two metastatic samples. We initially performed an unsupervised clustering to generate heatmaps ( Figure S1 ). The Canadian series provided the known class predictions for comparison to the subgroup findings from the Brazilian cohort. 25 Following normalization of raw data from both series (Canadian series combined with the Brazilian series; Figure S1 ), the PAM method was applied for class prediction. Employing a machine learning approach, we successfully classified all medulloblastoma samples according to molecular subgroups (Figs 1, 2A) . The probability of each subgroup for all samples and the highest probability index for specific molecular subgroups was considered for the final classification. Most samples in each subgroup presented a probability rate higher than 90%. Therefore, the final proportions for classification of the Brazilian medulloblastoma subgroups was 49% MB SHH (n = 51), 18% MB WNT (n = 19), 14% MB GRP3 (n = 15) and 18% MB GRP4 (n = 19) (Figs 1, 2A ; Table 1 ). Interestingly, for the two patients (patients #87 and #98; Table S1) in which both primary and metastatic tissue could be evaluated, each pair exhibited the same molecular profile (MB SHH ).
Association of molecular subgroups with clinicopathological features
Clinical and molecular features of the molecular subgroup are summarized in Table 1 and described in detail in Table S1 . Older age patients were strongly associated with the MB SHH subgroup and younger patients with MB GRP3 (P < 0.0001; Table 1 ). No association by age category (< 4, 5-19 and > 20 years) and disease outcome was observed (P = 0.1). The female gender was strongly associated with MB WNT (P < 0.0001; Table 1 ). Univariate analysis indicated a trend of association between disease-specific OS and medulloblastoma molecular subgroup (log-rank test: P = 0.07; Fig. 2B ; Table S2 ). The highest 5-year disease-specific OS was observed for the MB WNT (100%) subgroup, followed by MB GRP3 (73%), MB SHH (64%) and MB GRP4 (63%).
Multivariate analysis showed a higher hazard ratio (HR) for patients who underwent partial surgical resection (HR = 3.73, P = 0.006; Table 2 ), but no increased HR was observed for age, gender, metastasis at diagnosis, or for molecular subgroup (Table 2) .
hTERT mutational status
Hotspot hTERT promoter mutations (−124 bp G > A and -146 bp G > A) were successfully sequenced in 73.1% (76/104) of tumors. Of these, 29% (22/76) of the cases were mutated (Fig. 3A) , with 82% (18/22) harboring the -124 bp G > A mutation and 18% (4/22) the -146 bp G > A mutation. The frequency of hTERT mutations was significantly higher in the MB SHH subgroup (77%), than in MB WNT (9%), MB GRP4 (9%), and MB GRP4 (5%) (p = 0.002; Table 1; Table S1 ). The distribution of hTERT mutation was associated with older age as follows: 4.5% (1/22) of mutated cases in patients ≤ 4 years old, 36.4% (8/22) of mutated cases between 5 and 19 years old, and 59.1% (13/22) of mutated cases in patients more than 20 years old (P = 0.002). We extended our analysis to determine whether hTERT mutational status correlated with hTERT gene expression assessed in the NanoString gene panel, and we found that hTERT mutated tumors exhibited a significantly increased hTERT expression (P = 0.03; Fig. 3B ). Since most of the hTERT mutated cases belonged to the MB SHH subgroup, we also evaluated whether hTERT mutational status and hTERT expression correlated with OS in this specific subgroup, but no association was observed (P = 0.41 and 0.31, respectively). Moreover, neither hTERT mutational status nor hTERT expression was associated with OS (P = 0.34 and P = 0.72, respectively; Fig. 3C, D) .
DISCUSSION
Four major medulloblastoma molecular subgroups (MB WNT, MB SHH, MB GRP3, MB GRP4 ) have been described based on specific molecular characteristics, such as mutations and differential expressions of key genes. [14] [15] [16] [17] 30 The assignment of medulloblastoma molecular subgroups plays an important role in patient prognostication, 30, 31 and may also be crucial in the design of potential targeted therapies. Herein, we have successfully implemented an effective approach for medulloblastoma molecular subgrouping using FFPE from 104 cases from Brazilian health centers. Additionally, we reported the main clinical and molecular characteristics for each molecular subgroup. The molecular pathogenesis of medulloblastomas has been partially elucidated by microarray expression profiling and, until recently, this high-throughput technique was the best approach in determining medulloblastoma molecular subgroups. 14, 15, 30 However, these earlier platforms required large amounts of high-quality RNA, presented a high variability and are expensive, limiting their application as a routine diagnostic approach. Since there is no current gold-standard method for medulloblastoma molecular subgrouping, the implementation of a robust and inexpensive method is urgently needed. For this reason, Dr. Taylor's group developed the 22-gene panel for the assignment of medulloblastoma molecular subgroups employing an innovative platform (nCounter ® system; NanoString) applied to FFPE samples, which are routinely collected for histopathological analysis. 25 For actual assignment of the medulloblastoma molecular subgroups based on high-throughput gene expression, it is necessary to employ class prediction analysis. Several algorithms were previously tested by Dr. Taylor's group and the PAM method presented the best scoring index with the lowest misclassification rates compared with other statistical approaches. 25 This method is faster and can improve accuracy by reducing the effect of intrinsic noise from highly expressed genes, providing easily interpretable results for biologists and clinicians. 29 For this reason, the PAM method was employed for class prediction in the present study. The gene expression analysis employing the nCounter ® technology using the 22-gene panel together with the PAM method for class prediction could classify according to molecular subgroups all medulloblastoma samples analyzed. We also observed the concordance of molecular subgroups in paired primary and metastatic tissues in two patients in accordance with previous data. 32 In our series, the majority of cases (49%) were classified in the MB SHH subgroup, followed by MB WNT (18%), MB GRP4 (18%) and MB GRP3 (14%). These frequencies differ slightly from the reported series, that reported higher frequencies of MB GRP3 (20-26%) and MB GRP4 (35-37%), which could be explained, at least in part, by the older age (18 years average) of our cohort in comparison with other studies.
25,31 Hotspot hTERT somatic mutations have been reported in medulloblastomas with frequencies ranging 4-27%. [20] [21] [22] 33, 34 In the present study, hTERT mutations were observed in 29% of the cases, and these mutations were more frequent in MB SHH as previously described 21, 22 Moreover, hTERT mutations were associated with olderaged patients in accordance with previous studies. 20, 35 Since hTERT-activating promoter mutations are reported to enhance telomerase expression, 27 we included the hTERT gene in the CodeSet of the 22-gene panel for medulloblastoma molecular subgrouping. Unsurprisingly, we observed that hTERT mutated cases also exhibited a higher hTERT expression.
In the current study, no association was observed between the molecular features (molecular subgroups, hTERT mutations status and hTERT expression) and OS in the multivariate analysis. Due to the retrospective and multicentric nature of this study, patients were not treated uniformly, which hampers proper outcome analysis.
Our study illustrates the robustness of the NanoString gene expression profiling of FFPE samples, since all 106 cases from different Brazilian institutions provided reliable subgroup classifications. This finding is important because samples from different institutions are likely to have different pre-analytic protocols. Of note, most of the samples in our study had been stored for several years, some of them for more than 20, leading to high levels of nucleic acid degradation, as demonstrated by the difficulties identifying mutational status using traditional analytical methods from the hTERT gene for a subset of cases. These findings suggest that molecular profiling of the 22-gene panel will be important for future medulloblastoma clinical trials utilizing RNA from FFPE samples. Importantly, in the revised 2016 WHO CNS classification, a meaningful integration of genetic/biological information with histopathological features is suggested to enable a more precise medulloblastoma classification. 26 In this context, the present mRNA-based 22-gene panel accurately discriminates the four genetically defined medulloblastoma subgroups, which are MB WNT , MB SHH and non-MB WNT / non-MB SHH (MB GRP3 and MB GRP4 ). 26, 36, 37 Yet, in the update of WHO classification, the MB SHH subgroup should further divided in accordance with TP53 status that differentiates two different MB SHH disease entities, displaying distinct genetic features, age of diagnosis and outcome. [36] [37] [38] Concluding, we successfully implemented the 22-gene panel originally described by Northcott and colleagues for medulloblastoma molecular classification in a multicenter Brazilian cohort of FFPE cases employing the nCounter ® technology. Our findings demonstrate the feasibility of medulloblastoma molecular subgrouping in a routine clinical testing.
